Immune surveillance of human cancer: If the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?

Tissue Antigens

Volumn 75, Issue 1, 2010, Pages 1-8

  Hamai A ^a   Benlalam, H ^a   Meslin, F ^a   Hasmim, M ^a   Carre T ^a   Akalay, I ^a   Janji, B ^b   Berchem, G ^b   Noman, M Z ^a   Chouaib, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Cytoskeleton; EMT; Endothelial cells; Metastasis; P53; Specific lysis; Tumor hypoxia; Tumor resistance

Indexed keywords

GRANZYME B; HYPOXIA INDUCIBLE FACTOR; PROTEIN P53;

CANCER GROWTH; CANCER RESISTANCE; CELL DEATH; CELL TRANSFORMATION; CYTOLYSIS; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; HUMAN; HYPOXIA; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MICROENVIRONMENT; MICROSATELLITE INSTABILITY; NEOPLASM; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STROMA;

ANIMALS; ANTIGENS, NEOPLASM; CELL COMMUNICATION; CELL DEATH; CONNECTIVE TISSUE; CYTOSKELETON; ENDOTHELIAL CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; MICE; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 72649104033     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01401.x     Document Type: Review

References (46)

1. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001 : 2 : 293 299.
2. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997 : 18 : 493 497.
3. Anichini A, Molla A, Mortarini R et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999 : 190 : 651 667.
4. Janke J, Schluter K, Jandrig B et al. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med 2000 : 191 : 1675 1686.
5. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008 : 371 : 771 783.
6. Thiery J, Dorothee G, Haddada H et al. Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J Immunol 2003 : 170 : 5919 5926.
7. Thiery J, Abouzahr S, Dorothee G et al. p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol 2005 : 174 : 871 878.
8. Abouzahr S, Bismuth G, Gaudin C et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci USA 2006 : 103 : 1428 1433.
9. Abouzahr-Rifai S, Hasmim M, Boukerche H et al. Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation. J Biol Chem 2008 : 283 : 31665 31672.
10. Glinsky GV, Glinsky VV. Apoptosis amd metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 1996 : 101 : 43 51.
11. Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 1997 : 115 : 185 193.
12. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003 : 22 : 3152 3161.
13. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003 : 22 : 3138 3151.
14. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006 : 6 : 449 458.
15. Hamai A, Meslin F, Benlalam H et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res 2008 : 68 : 9854 9864.
16. Jenkinson SR, Williams NA, Morgan DJ. The role of intercellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. J Immunol 2005 : 174 : 3401 3407.
17. Yasuda M, Tanaka Y, Tamura M et al. Stimulation of beta1 integrin down-regulates ICAM-1 expression and ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase. Cancer Res 2001 : 61 : 2022 2030.
18. Kuhn JR, Poenie M. Dynamic polarization of the microtubule cytoskeleton during CTL-mediated killing. Immunity 2002 : 16 : 111 121.
19. Stinchcombe JC, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 2001 : 15 : 751 761.
20. van der Merwe PA. Formation and function of the immunological synapse. Curr Opin Immunol 2002 : 14 : 293 298.
21. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005 : 17 : 251 258.
22. Lefor AT, Fabian DF. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J Surg Res 1998 : 75 : 49 53.
23. Sartor WM, Kyprianou N, Fabian DF, Lefor AT. Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J Surg Res 1995 : 59 : 66 74.
24. Turner J, Rhee JG, Fabian DF, Lefor AT. Expression of ICAM-1 enhances in vivo lymphocyte adhesion in a murine fibrosarcoma. J Surg Oncol 1997 : 66 : 39 44.
25. Johnson JP, Lehmann JM, Stade BG, Rothbacher U, Sers C, Riethmuller G. Functional aspects of three molecules associated with metastasis development in human malignant melanoma. Invasion Metastasis 1989 : 9 : 338 350.
26. Natali P, Nicotra MR, Cavaliere R et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990 : 50 : 1271 1278.
27. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006 : 7 : 131 142.
28. Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol 2004 : 14 : R719 21.
29. Cho HJ, Baek KE, Saika S, Jeong MJ, Yoo J. Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun 2007 : 353 : 337 343.
30. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009 : 15 : 195 206.
31. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006 : 441 : 437 443.
32. Frederiksen LJ, Sullivan R, Maxwell LR et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007 : 13 : 2199 2206.
33. Postovit LM, Sullivan R, Adams MA, Graham CH. Nitric oxide signalling and cellular adaptations to changes in oxygenation. Toxicology 2005 : 208 : 235 248.
34. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007 : 26 : 319 331.
35. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004 : 9 (Suppl 5) : 10 7.
36. Hussain SF, Kong LY, Jordan J et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007 : 67 : 9630 9636.
37. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009 : 69 : 2506 2513.
38. Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009 : 69 : 2514 2522.
39. Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest 2003 : 111 : 595 597.
40. Bellot G, Garcia-Medina R, Gounon P et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009 : 29 : 2570 2581.
41. Mellor HR, Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev 2007 : 26 : 553 566.
42. Wilkinson S, O'Prey J, Fricker M, Ryan KM. Hypoxiaselective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev 2009 : 23 : 1283 1288.
43. Limmer A, Ohl J, Kurts C et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD 8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000 : 6 : 1348 1354.
44. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD 8+ T cells. J Exp Med 2003 : 197 : 643 656.
45. Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002 : 3 : 844 851.
46. Benlalam H, Jalil A, Hasmim M et al. Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. J Immunol 2009 : 182 : 2654 2664.